- 04/27/2020
- EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN “THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING)” BY INSTITUTIONAL INVESTOR MAGAZINE
- 04/01/2020
- Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
- 03/27/2020
- The 6th Eisai China’s GIVE Forum (Webinar) Held Successfully
- 03/26/2020
- EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA
- 03/22/2020
- 2020 Eisai Empowering Neurology’s Future Summit (Online) Kicks Off
- 03/02/2020
- Eisai China escorts you to tide over the crisis
- 02/25/2020
- Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
- 02/21/2020
- EISAI RECEIVES THE PRESIDENT’S AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDS
- 01/28/2020
- 01/10/2020
- LAUNCH OF ANTICANCER AGENT HALAVEN® IN CHINA
